{"doi":"10.3109/00498254.2011.632030","title":"Effects of the<i>SLCO1B1*15</i>allele on the pharmacokinetics of pitavastatin","abstract":null,"journal":"Xenobiotica","year":2012,"id":607932,"datarank":0.4335557636844247,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"self_citation_contribution":0.4335557636844247,"citation_network_contribution":0.0,"self_endowment_contribution":0.4335557636844247,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":17,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1561127,"name":"Yun-Jeong Lee","orcid":null,"position":1,"is_corresponding":false},{"id":667980,"name":"Hye-In Lee","orcid":"0000-0002-7062-616X","position":2,"is_corresponding":false},{"id":1561128,"name":"Bo-Hye Kim","orcid":null,"position":3,"is_corresponding":false},{"id":1561129,"name":"Mi-Jeong Kim","orcid":null,"position":4,"is_corresponding":false},{"id":1561130,"name":"Choon-Gon Jang","orcid":null,"position":5,"is_corresponding":false},{"id":1561131,"name":"Jung-Woo Bae","orcid":null,"position":6,"is_corresponding":false},{"id":1536751,"name":"Seok-Yong Lee","orcid":null,"position":7,"is_corresponding":false},{"id":1561126,"name":"Chang-Ik Choi","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effects of the<i>SLCO1B1*15</i>allele on the pharmacokinetics of pitavastatin","abstract":"The hepatic uptake of pitavastatin is mediated by carriers, especially OATP1B1, which is encoded by the SLCO1B1 gene. Because the liver is a target organ of pitavastatin, OATP1B1 is responsible for both the pharmacological effects and clearance of pitavastatin. The effects of the SLCO1B1*15 allele on the pharmacokinetics (PK) of pitavastatin were studied. Pitavastatin 2 mg was orally administered to 38 subjects with SLCO1B1*1a/*1b (n = 20), *1b/*15 (n = 13), or *15/*15 (n = 5). After pitavastatin administration, the plasma concentrations of pitavastatin and pitavastatin lactone were assayed for up to 48 h using liquid chromatography-tandem mass spectrometry. In comparison to the SLCO1B1*1a/*1b subjects, only a C(max) was slightly higher in the SLCO1B1*1b/*15 subjects. However, the SLCO1B1*15/*15 subjects had a 1.74-fold higher AUC(inf) (285.5 ± 14.5 vs. 164.6 ± 41.3 ng·h/mL; p < 0.001), a 2.21-fold higher C(max) (106.7 ± 15.1 vs. 48.3 ± 13.4 ng/mL; p < 0.001), and a 47.3% lower apparent oral clearance (13.1 ± 3.9 vs. 6.9 ± 0.4 L/h; p < 0.001) of pitavastatin. For pitavastatin lactone, there were no significant differences in AUC(inf), C(max), t(1/2), and t(max) among the three genotypes. Unlike previous studies, the disposition of pitavastatin exposure was not altered in subjects with the SLCO1B1*1b/*15 genotype, except C(max). However, pitavastatin exposure was significantly increased in subjects with the SLCO1B1*15/*15 genotype due to reduced hepatic absorption.","is_dataset_classified":null,"base_score":2.8903717578961645,"endowment":2.8903717578961645,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"22077103","pmcid":null,"openalex_id":"https://openalex.org/W1983187578","authors":[],"funders":[],"total_grants":0,"fwci":0.7803,"citation_percentile":0.71146937,"influential_citations":0,"citation_trend":[{"year":2012,"count":3},{"year":2013,"count":2},{"year":2014,"count":1},{"year":2016,"count":1},{"year":2018,"count":1},{"year":2019,"count":1},{"year":2020,"count":1},{"year":2023,"count":2},{"year":2024,"count":3},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.3109/00498254.2011.632030","host_type":"publisher"},{"url":"https://doi.org/10.3109/00498254.2011.632030","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/22077103","host_type":"repository"}],"fields_of_study":["Drug Transport and Resistance Mechanisms","Liver Disease Diagnosis and Treatment","Cancer, Lipids, and Metabolism"],"mesh_terms":["Administration, Oral","Alleles","Dose-Response Relationship, Drug","Humans","Quinolines","Time Factors","Organic Anion Transporters","Liver-Specific Organic Anion Transporter 1"],"keywords":["Pitavastatin","SLCO1B1","Cmax","Pharmacokinetics","Pharmacology","Chemistry","Organic anion transporter 1","Genotype","Internal medicine","Medicine","Pharmacogenetics","Transporter","Biochemistry","Gene"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T07:14:32.975249Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}